6514 ORAL Adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study evaluating the MAGE-A3 cancer immunotherapeutic

Vansteenkiste, Johan; Zieliński, Marcin; Linder, A.; Dahabre, J; Esteban, Emilio; Malinowski, Wojciech; Jassem, J; Passlick, Bernward; López‐Brea, Marta; Vanakesa, Tônu

doi:10.1016/s1359-6349(07)71342-3

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This property makes them interesting players in terms of tumor vaccination. For example, in non-small cell lung cancer (NSCLC) patients, MAGE-A3 vaccine has been shown to contribute to the reduction of recurrence rates compared with the control group (18). This study was designed to evaluate the prognostic value of all known MAGE-A antigens in terms of response to chemotherapy.…”

Section: Mage-a Expression Clusters and Antineoplastic Treatment In Hmentioning

confidence: 99%

MAGE-A expression clusters and antineoplastic treatment in head and neck cancer

Hartmann

Meyer

Brands

et al. 2015

International Journal of Molecular Medicine

View full text Add to dashboard Cite

The nonsurgical treatment of head and neck squamous cell carcinoma (HNSCC) usually consists of radiation and chemotherapy. In general, the treatment efficacy of chemotherapy in head and neck cancer is limited. Apart from the placenta, testis and fetal keratinocytes, melanoma-associated antigens-A (MAGE-A) are only found in malignancies. Even though their molecular role remains unclear, several subgroups have been found to contribute to resistance to different chemotherapeutic agents. In the present study, established human squamous cell carcinoma cell lines were incubated with various concentrations of cisplatin, 5-fluorouracil, paclitaxel, docetaxel, cetuximab and panitumumab for 5, 10, 20 and 40 h. The treatment efficacy was measured dynamically by real-time cell analysis (RTCA). In addition, we determined the expression of all known MAGE-A subgroups (MAGE-A1 to MAGE-A12, excluding pseudogene MAGE-A7) by reverse transcription quantitative polymerase chain reaction. Of note, one cell line showed only a marginal expression of MAGE-A antigens, whereas another cell line showed a distinct expression of almost all the MAGE-A subgroups. The expression pattern varied in the other cell lines. MAGE-A4 was the most highly expressed of all the subgroups, and MAGE-A8 could not be detected. With the exception of MAGE-A6, -A8, -A9 and -A10, the expression levels differed significantly between the cell lines. Factor analysis suggested simplifying the MAGE-A expression level into two groups. Spearman's rank correlation revealed a significant association between MAGE-A expression and treatment efficacy for 20.8% (25/120) of the experiments. In 100% of these cases (25/25), Spearman's Rho revealed a positive correlation between clustered MAGE-A expression and poor treatment efficacy. Our data highlight the fact that higher a MAGE-A expression correlates with a poorer outcome of antineoplastic treatment. Clustered MAGE-A expression analysis may help to identify patients who are at a higher risk of antineoplastic treatment failure.

show abstract

Section: Mage-a Expression Clusters and Antineoplastic Treatment In Hmentioning

confidence: 99%

MAGE-A expression clusters and antineoplastic treatment in head and neck cancer

Hartmann

Meyer

Brands

et al. 2015

International Journal of Molecular Medicine

View full text Add to dashboard Cite

show abstract

“…A recombinant MAGE-A3 fusion protein has been used for immunization, and resulted in the induction of CD4 + and CD8 + T cell responses, as well as B cell responses [27]. Recently, the final results of a multi-center, double-blind, randomized, placebo-controlled phase II study evaluating the MAGE-A3 cancer immunotherapy have been reported [28,29]. In the adjuvant setting, 122 resected MAGE-A3-positive stage IB/II NSCLC patients who received a series of five vaccinations at 3-week intervals experienced an improvement of disease-free survival.…”

Section: Melanoma-associated Antigen E-a3 Protein Vaccine (Mage-a3)mentioning

confidence: 99%

Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer

Kakimi¹,

Nakajima²,

Wada³

2009

Lung Cancer

View full text Add to dashboard Cite

Non-small-cell lung carcinoma vaccines in clinical trials

Rossi

Maione

Schettino

et al. 2011

Expert Review of Vaccines

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) is not considered to be immunogenic, but it may provide an accessible target for the properly primed immune system. Identifying lung tumor antigens and presenting them in the optimal context may enable the immune system to generate anti-lung tumor effector cells, which are usually absent. Despite encouraging preclinical and Phase I-II data, no specific active cancer vaccine has been approved for NSCLC therapy to date. Patient selection and measurable immune response methodology assessment could explain these negative results. Vaccine therapy has recently been re-emerging as a potential approach. This article discusses the Phase I, II and III trials investigating the most promising vaccines in the treatment of patients affected by any stage of NSCLC, thus providing a perspective on the future of this approach in this setting.

show abstract

6514 ORAL Adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study evaluating the MAGE-A3 cancer immunotherapeutic

Cited by 4 publications

References 0 publications

MAGE-A expression clusters and antineoplastic treatment in head and neck cancer

MAGE-A expression clusters and antineoplastic treatment in head and neck cancer

Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer

Non-small-cell lung carcinoma vaccines in clinical trials

Contact Info

Product

Resources

About